TNXP

NASDAQ Healthcare

Tonix Pharmaceuticals Holding Corp. - Common Stock

Biotechnology

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

๐Ÿ“Š Market Data
Price$13.60
Volume349,236
Market Cap193.19M
Beta1.760
RSI (14-Day)55.2
200-Day MA$21.77
50-Day MA$13.76
52-Week High$69.97
52-Week Low$11.60
Forward P/E-2.64
Price / Book0.71
๐ŸŽฏ Investment Strategy Scores

TNXP scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 88/100โ–ผ -1
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 96/100โ–ผ -1
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 48/100โ–ฒ +10
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (96/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐Ÿ‹ Institutional Whale (3/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find TNXP in your text

Paste any article, transcript, or post โ€” the tool will extract TNXP and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.